# Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD

> **NCT05885841** · PHASE2 · COMPLETED · sponsor: **Sinotau Pharmaceutical Group** · enrollment: 83 (actual)

## Conditions studied

- Coronary Artery Disease (CAD)

## Interventions

- **DRUG:** XTR004

## Key facts

- **NCT ID:** NCT05885841
- **Lead sponsor:** Sinotau Pharmaceutical Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-15
- **Primary completion:** 2023-05-09
- **Final completion:** 2023-05-09
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2023-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05885841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05885841, "Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05885841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*